PrIME Biologics Pte Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:PrIME Biologics Pte Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12369
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:16
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:シンガポール
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
PrIME Biologics Pte Ltd (PrIME Biologics) is a biotechnology company that develops and manufactures plasma products for human use. The company uses Preparative Isolation by Membrane Electrophoresis ((PrIME) technology, a disposable, fully-scalable and modular manufacturing process, to manufacture its products. It also carries out employing the natural charge found on proteins of various organisms. PrIME process facilitates the hugely selective purification of the target molecules. The company’s cellular membranes in nature also consist of a charge, indicating that pathogens such as viruses and bacteria can also be selectively eliminated by this system. Its manufacturing plasma based therapeutic proteins for various uses. PrIME Biologics operates in Singapore and Australia. PrIME Biologics is headquartered in Singapore.

PrIME Biologics Pte Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
PrIME Biologics Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PrIME Biologics Pte Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
PrIME Biologics Pte Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PrIME Biologics Pte Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 8
PrIME Biologics Pte Ltd, Pharmaceuticals & Healthcare, Deal Details 9
Venture Financing 9
PrIME Biologics Raises USD12.5 Million in Venture Financing 9
Private Equity 10
PrIME Biologics To Raise US$12 Million In Private Equity Financing 10
PrIME Biologics To Raise US$15.8 Million In Private Equity Financing 11
Acquisition 12
A-Bio Pharma To Acquire 10% Stake In PrIME Biologics From NuSep For US$4.8 Million 12
PrIME Biologics Pte Ltd – Key Competitors 13
PrIME Biologics Pte Ltd – Key Employees 14
PrIME Biologics Pte Ltd – Locations And Subsidiaries 15
Head Office 15
Appendix 16
Methodology 16
About GlobalData 16
Contact Us 16
Disclaimer 16

List of Tables
PrIME Biologics Pte Ltd, Pharmaceuticals & Healthcare, Key Facts 2
PrIME Biologics Pte Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 2
PrIME Biologics Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PrIME Biologics Pte Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
PrIME Biologics Pte Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PrIME Biologics Pte Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 8
PrIME Biologics Raises USD12.5 Million in Venture Financing 9
PrIME Biologics To Raise US$12 Million In Private Equity Financing 10
PrIME Biologics To Raise US$15.8 Million In Private Equity Financing 11
A-Bio Pharma To Acquire 10% Stake In PrIME Biologics From NuSep For US$4.8 Million 12
PrIME Biologics Pte Ltd, Key Competitors 13
PrIME Biologics Pte Ltd, Key Employees 14

List of Figures
PrIME Biologics Pte Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
PrIME Biologics Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
PrIME Biologics Pte Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
PrIME Biologics Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PrIME Biologics Pte Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
PrIME Biologics Pte Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

★海外企業調査レポート[PrIME Biologics Pte Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • JHL Biotech Inc:医療機器:M&Aディール及び事業提携情報
    Summary JHL Biotech Inc (JHL Biotech) is a biologic medicines provider. The company offers cell line construction, process development, manufacturing, quality and regulatory services. It offers products such as biosimilar rituximab, biosimilar dornase alfa, biosimilar bevacizumab, biosimilar trastuz …
  • Genfit SA (GNFT):企業の財務・戦略的SWOT分析
    Summary Genfit SA (Genfit) is a biopharmaceutical company that develops therapeutic and diagnostic solutions for metabolic and inflammatory diseases in liver and gastroenterology diseases. The company’s pipeline products include GFT505, biomarkers, TGFTX1 and TGFTX4. Its TGFTX1 is a research program …
  • Electricity & Water Authority:企業の戦略的SWOT分析
    Electricity & Water Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • AC Immune SA (ACIU):企業の財務・戦略的SWOT分析
    AC Immune SA (ACIU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Almaty International Airport JSC:企業の戦略・SWOT・財務分析
    Almaty International Airport JSC - Strategy, SWOT and Corporate Finance Report Summary Almaty International Airport JSC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Washington University School of Medicine-製薬・医療分野:企業M&A・提携分析
    Summary Washington University School of Medicine (WUSTL), a subsidiary of University of Washington is a medical university that offers patient care, research, education services and neurology clinical trials. The university provides patient care services such as clinical, find a doctor, referring ph …
  • Aarti Drugs Ltd (AARTIDRUGS):企業の財務・戦略的SWOT分析
    Summary Aarti Drugs Ltd (ADL), a subsidiary of Aarti Group of Industries is a contract manufacturer of pharmaceutical products that offers therapeutic products, ingredients, bulk drugs, and chemicals. The company's products include active pharmaceutical ingredients, pharma intermediates, and special …
  • Omnicell Inc (OMCL)-医療機器分野:企業M&A・提携分析
    Summary Omnicell Inc (Omnicell) is a provider of automation and business analytics software solutions. It provides medication control and patient safety solutions to enhance operational efficiency and patient care in acute healthcare facilities. The company offers automation solutions such as medica …
  • E.ON UK Plc:企業の発電所・SWOT分析2018
    E.ON UK Plc - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (execut …
  • Bouwinvest Real Estate Investment Management B.V.:企業の戦略・SWOT・財務情報
    Bouwinvest Real Estate Investment Management B.V. - Strategy, SWOT and Corporate Finance Report Summary Bouwinvest Real Estate Investment Management B.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structur …
  • Empresas Copec S.A.:企業の戦略・SWOT・財務分析
    Empresas Copec S.A. - Strategy, SWOT and Corporate Finance Report Summary Empresas Copec S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • OBI Pharma Inc (4174):医療機器:M&Aディール及び事業提携情報
    Summary OBI Pharma Inc (OBI Pharma) is a biopharmaceutical company that develops therapies for the treatment of cancer and infectious diseases. The company’s products include adagloxad simolenin, an active immunotherapy which is intended for the treatment of metastatic breast cancer; and OBI-833, a …
  • Industrias Nucleares do Brasil SA:企業の戦略的SWOT分析
    Industrias Nucleares do Brasil SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Bunzl plc (BNZL):企業の財務・戦略的SWOT分析
    Bunzl plc (BNZL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • P.T. Telekomunikasi Selular:企業の戦略・SWOT・財務情報
    P.T. Telekomunikasi Selular - Strategy, SWOT and Corporate Finance Report Summary P.T. Telekomunikasi Selular - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Avanir Pharmaceuticals Inc:企業の戦略的SWOT分析
    Avanir Pharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • OpGen Inc (OPGN):企業の財務・戦略的SWOT分析
    OpGen Inc (OPGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • HSH Nordbank Private Banking:企業の戦略・SWOT・財務情報
    HSH Nordbank Private Banking - Strategy, SWOT and Corporate Finance Report Summary HSH Nordbank Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • OncoMed Pharmaceuticals Inc (OMED):製薬・医療:M&Aディール及び事業提携情報
    Summary OncoMed Pharmaceuticals Inc (OncoMed) is a clinical-stage biopharmaceutical company focused on discovery and development of novel immuno-oncology (IO) therapeutics for the treatment of cancers. Its pipeline product candidates include navicixizumab, rosmantuzumab, Gitrl-FC Trimer, and anti-TI …
  • Skyworth Digital Holdings Limited:企業の戦略・SWOT・財務分析
    Skyworth Digital Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Skyworth Digital Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆